Summary
Marine organisms have the capacity to produce a variety of biologically potent natural products. Such novel molecules have new mechanisms of action and therefore could be used to treat human diseases and enhance the quality of life, especially in the ageing segment of the population. However, although there is growing interest in marine natural products (MNP) as potential therapeutic agents for human age-related diseases, few MNPs have reached clinical trials and the market. To fully exploit these promising biological resources, new strategies in the pipeline as well as a new cohort of cross-disciplinary trained scientists are needed to overcome existing bottlenecks and ensure the production of high value biomolecules.
Ocean Medicines is a network of academic, research centres and SMEs across Europe, with proven experience in higher education, training and endowed with state-of-the art scientific and technical expertise and infrastructures.
Our aim is to establish a network of collaboration and knowledge-exchange between industrial and academic partners to further develop lead compounds from marine microorganisms having anticancer or anti-infective effects that have already been identified by the consortium.
To achieve this a secondment programme will be set up to prepare a new generation of marine biodiscovery scientists that will be trained on how to isolate compounds from bioactive bacteria/microalgae and take these through to semi-industrial scale-up for further development and toxicity testing at the pre-clinical level.
The Ocean Medicines programme also considers commercialization, innovation and entrepreneurship activities including how to start a new business and how to favour an industrial career to seconded researchers. We are confident that the establishment of this international research network, with its synergistic effects, will significantly contribute to advance all of the involved labs to the top level in the field of marine drug discovery.
Ocean Medicines is a network of academic, research centres and SMEs across Europe, with proven experience in higher education, training and endowed with state-of-the art scientific and technical expertise and infrastructures.
Our aim is to establish a network of collaboration and knowledge-exchange between industrial and academic partners to further develop lead compounds from marine microorganisms having anticancer or anti-infective effects that have already been identified by the consortium.
To achieve this a secondment programme will be set up to prepare a new generation of marine biodiscovery scientists that will be trained on how to isolate compounds from bioactive bacteria/microalgae and take these through to semi-industrial scale-up for further development and toxicity testing at the pre-clinical level.
The Ocean Medicines programme also considers commercialization, innovation and entrepreneurship activities including how to start a new business and how to favour an industrial career to seconded researchers. We are confident that the establishment of this international research network, with its synergistic effects, will significantly contribute to advance all of the involved labs to the top level in the field of marine drug discovery.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/690944 |
| Start date: | 01-12-2015 |
| End date: | 30-11-2019 |
| Total budget - Public funding: | 360 000,00 Euro - 360 000,00 Euro |
Cordis data
Original description
Marine organisms have the capacity to produce a variety of biologically potent natural products. Such novel molecules have new mechanisms of action and therefore could be used to treat human diseases and enhance the quality of life, especially in the ageing segment of the population. However, although there is growing interest in marine natural products (MNP) as potential therapeutic agents for human age-related diseases, few MNPs have reached clinical trials and the market. To fully exploit these promising biological resources, new strategies in the pipeline as well as a new cohort of cross-disciplinary trained scientists are needed to overcome existing bottlenecks and ensure the production of high value biomolecules.Ocean Medicines is a network of academic, research centres and SMEs across Europe, with proven experience in higher education, training and endowed with state-of-the art scientific and technical expertise and infrastructures.
Our aim is to establish a network of collaboration and knowledge-exchange between industrial and academic partners to further develop lead compounds from marine microorganisms having anticancer or anti-infective effects that have already been identified by the consortium.
To achieve this a secondment programme will be set up to prepare a new generation of marine biodiscovery scientists that will be trained on how to isolate compounds from bioactive bacteria/microalgae and take these through to semi-industrial scale-up for further development and toxicity testing at the pre-clinical level.
The Ocean Medicines programme also considers commercialization, innovation and entrepreneurship activities including how to start a new business and how to favour an industrial career to seconded researchers. We are confident that the establishment of this international research network, with its synergistic effects, will significantly contribute to advance all of the involved labs to the top level in the field of marine drug discovery.
Status
CLOSEDCall topic
MSCA-RISE-2015Update Date
28-04-2024
Images
No images available.
Geographical location(s)
Search
Organisations
-
| CONSIGLIO NAZIONALE DELLE RICERCHE (CNR) (Coördinator)
-
| BIOSEARCH SRL
-
| ECOAST
-
| EPI-C SRL
-
| FUNDACION CENTRO DE EXCELENCIA EN INVESTIGACION DE MEDICAMENTOS INNOVADORES EN ANDALUCIA
-
| SEA4US BIOTECNOLOGIA E RECURSOS MARINHOS LDA
-
| SEALIFE PHARMA GMBH
-
| STAZIONE ZOOLOGICA ANTON DOHRN
-
| UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET (UiT)
-
| UNIVERSITY OF ABERDEEN
-
| UNIVERSITY OF THE WESTERN CAPE